Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, and the Boston University Chobanian & Avedisian School of Medicine, 801 Massachusetts Ave. 2nd Floor, Boston, MA 02118, USA.
Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave., Ste 1600, Seattle, WA 98101, USA.
Drug Alcohol Depend. 2024 Dec 1;265:112497. doi: 10.1016/j.drugalcdep.2024.112497. Epub 2024 Nov 10.
Implementation of office-based addiction treatment (OBAT) by nurse care managers increases overall use of OUD medication, but it is unknown whether it increases treatment duration among treated patients.
The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a pragmatic, cluster-randomized trial testing whether implementation of OBAT increased OUD treatment in 12 primary care clinics in 6 systems. One of 2 clinics per system was randomized to implement OBAT (intervention), the other, usual care (UC). We evaluated treatment duration for the 3 years after nurses began seeing patients at clinics randomized to intervention vs. UC. The primary sample included patients newly initiating OUD medication; the secondary sample included patients with ongoing OUD medication. The primary outcome was percentage of days with OUD medications after treatment initiation, modeled using linear generalized estimating equations (GEE). Modified Poisson GEE models assessed secondary outcomes (≥80 % of days covered, ≥6 months on treatment).
In adjusted analyses, the mean difference between intervention and UC in percent days treated was 6.3 % (95 % CI -9.6 %, 22.1 %) in the primary sample and 2.3 % (95 % CI -36.4 %, 31.8 %) in the secondary sample. There was no significant difference in treatment duration between intervention and UC patients in either primary or secondary outcomes.
Implementation of OBAT in this trial did not measurably increase duration of medication treatment among those treated for OUD compared to UC, suggesting that benefits of OBAT, at least in this trial, largely reflect increases in treatment access.
由护士护理经理实施的基于办公室的成瘾治疗(OBAT)会增加整体阿片类药物使用障碍(OUD)药物的使用,但尚不清楚它是否会增加接受治疗的患者的治疗持续时间。
初级保健阿片类药物使用障碍治疗(PROUD)试验是一项实用的、集群随机试验,旨在测试通过实施 OBAT 是否会增加 6 个系统中的 12 个初级保健诊所的 OUD 治疗。每个系统中的 2 个诊所随机分为实施 OBAT(干预组)和常规护理(UC)。我们评估了护士开始在随机分配到干预组与 UC 组的诊所治疗患者后 3 年内的治疗持续时间。主要样本包括新开始接受 OUD 药物治疗的患者;次要样本包括正在接受 OUD 药物治疗的患者。主要结果是治疗开始后 OUD 药物的天数比例,使用线性广义估计方程(GEE)进行建模。修正泊松 GEE 模型评估了次要结果(≥80%的天数覆盖,≥6 个月的治疗)。
在调整后的分析中,干预组与 UC 组在主要样本中的治疗天数百分比差异为 6.3%(95%CI-9.6%,22.1%),在次要样本中的差异为 2.3%(95%CI-36.4%,31.8%)。在主要和次要结局中,干预组和 UC 组的治疗持续时间均无显著差异。
在这项试验中,OBAT 的实施并没有在可比的基础上显著增加接受 OUD 治疗的患者的药物治疗持续时间,这表明 OBAT 的益处,至少在这项试验中,主要反映了治疗机会的增加。